India likely to get at least 4 new Covid-19 vaccines by end of 2021 | Details

Everyone is speaking about Covishield, Covaxin and Sputnik V – the three Covid-19 vaccines being administered in India. However, there are literally many different Covid-19 vaccines at the moment within the pipeline in India.

By the end of this yr, India is likely to have about half a dozen vaccines. This will cut back the hole between provide and demand and likewise convey down the costs.

Here’s all you want to know concerning the new vaccines.


Pune-based Serum Institute of India (SII) is manufacturing the Oxford AstraZeneca vaccine underneath the identify ‘Covishield’.

But other than that, additionally it is producing protein-based Covid-19 vaccine NVX-CoV2373 underneath the model identify ‘Covovax’. This vaccine was developed by US biotechnology firm Novovax. SII’s manufacturing of Covovax has already begun.

As of now, bridging research for Covovax are underway in India. Once Novavax will get the required approvals in phrases of efficacy trials overseas, it’s anticipated that SII will do the identical in India.

Covovax is anticipated to be rolled out in two to three months. Twenty crore doses of the vaccine are likely to be produced by December.


Not distant from SII, Gennova Biopharmaceuticals is one other firm primarily based in Pune. The firm has developed India’s first mRNA Covid-19 vaccine known as HGC019. Phase I trials for the vaccine candidate started final month and thus far 120 volunteers have been lined.

Gennova Biopharmaceuticals has been granted Rs 250 crore by the federal government. The firm’s vaccine candidate is likely to be launched early subsequent yr.


Bharat Biotech’s nasal vaccine candidate is at the moment underneath Phase I trials.

According to the producer, the intranasal vaccine BBV154 creates an immune response at the location of an infection (within the nasal mucosa). This helps to block each an infection and transmission of Covid-19.

Bharat Biotech, the corporate that additionally manufactures Covaxin, is anticipated to roll out ten crore doses of its nasal vaccine by the end of the yr.


Zydus Cadila in Gujarat is producing an intradermal Covid-19 vaccine known as ZyCoV-D. It is India’s first indigenously developed DNA vaccine candidate and is at the moment being examined on kids.

The firm is anticipated to present 5 crore doses by the end of the yr. ZyCoV-D is likely to be rolled out in a month’s time. Zydus Cadila will apply (*4*)


Hyderabad-based Biological E has developed a vaccine candidate known as Corbevax which is at the moment present process Phase 3 medical trials.

Corbevax is a protein sub-unit vaccine, comparable to inactivated whole-cell vaccines resembling Covaxin, and doesn’t include stay elements of the virus.

The authorities stated on Thursday that it’ll make an advance fee of Rs 1,500 crore to Biological E to reserve 30 crore doses of Corbevax.

Thirty crore doses of Corbevax are anticipated to be rolled out between August and December. Of these, at least 7.5 crore doses shall be accessible by September.


Additionally, Biological E can be making an mRNA vaccine. The firm has entered right into a licensing settlement with Providence Therapeutics Holdings to manufacture the Canadian firm’s mRNA Covid-19 vaccine in India.

The vaccine, named PTX-COVID19-B, is underneath growth in Canada at the second.


Biological E can be bringing Johnson and Johnson’s Covid-19 vaccine to India. The Indian firm has a deal to produce about 600 million doses of the vaccine known as Janssen.

Janssen has already been accredited to be used within the United States, the European Union, Thailand and South Africa amongst others.


In India, six corporations will produce Russia’s Covid vaccine Sputnik V. This vaccine is anticipated to be probably the most utilized in India, other than Covishield and Covaxin, primarily based on the way in which during which its manufacturing is being ramped up.

The manufacturing corporations embrace Hetero Biopharma, Gland Pharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Serum Institute of India. The corporations are on observe to make hundreds of thousands of doses of the Russian vaccine in a bid to alleviate the nation’s present vaccine scarcity.


Indian corporations are additionally wanting to use their manufacturing capabilities to ramp up manufacturing of overseas vaccines by way of know-how switch.

Cipla is shut to committing one billion {dollars} upfront fee for Moderna’s booster vaccine in India. Wockhardt has additionally stated it intends to get the know-how switch of Covid-19 vaccines so as to manufacture two billion doses in India.

India prides itself on being the pharmacy to the world. As of now, the nation’s plan of augmenting vaccination capability so as to inoculate greater than a billion folks appears on observe.

However, India could have to be ready for challenges within the kind of new variants, vulnerability of kids and so forth.

ALSO READ: PM Modi lauds scientists for developing made-in-India Covid-19 vaccines in a year

ALSO READ: Punjab govt withdraws decision to sell Covid vaccines to private hospitals

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.